Sign in
WithdrawnNo phase

Artificial Intelligence in Mammography-Based Breast Cancer Screening

Key facts

Who runs it
Chinese University of Hong Kong
Where
Hong Kong1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Started
1 Jul 2020
Ended
31 Dec 2023
Type of study
Observational
Treatments tested
  • mammography
Record updated
7 February 2024
Why it stopped
the collaborating party of AI system withdraw their study due to change of company policy in year of COVID-19 pandemic

Who can take part

Sex
Women only
Healthy volunteers
Can take part
Show the full registry criteria (7)Hide the full registry criteria

Who can take part

  • Women who had undergone standard mammography including craniocaudal (CC) and mediolateral oblique (MLO) views
  • Histopathology-proven diagnosis is available for patients with breast malignancy, including invasive breast cancer, carcinoma in situ, and borderline lesion et al
  • As reference standard of benign nature, results from pathology or clinical long-term follow-up (>=2 years) examinations are available for cases without breast malignancy

Who cannot take part

  • Patients who had undergone breast surgical intervention (e.g. lumpectomy and mammoplasty) prior to first mammography
  • Patients diagnosed with other kinds of malignancy, concurrent with metastasis or infiltration/invasion to breast
  • Patients without available pathologic diagnosis or long-term follow-up (>=2 years) examinations
  • Patients with concurring lesions on mammograms that may influence subsequent AI post-process

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Breast cancer (BC) is the most common cancer among women in worldwide and the second leading cause of cancer-related death.

Read full original descriptionShow less

As the corner stone of BC screening, mammography is recognized as one of useful imaging modalities to reduce BC mortality, by virtue of early detection of BC. However, mammography interpretation is inherently subjective assessment, and prone to overdiagnosis.

In recent years, artificial intelligence (AI)-Computer Aided Diagnosis (CAD) systems, characterized by embedded deep-learning algorithms, have entered into the field of BC screening as an aid for radiologist, with purpose to optimize conventional CAD system with weakness of hand-crafted features extraction. For now, stand-alone performance of novel AI-CAD tools have demonstrated promising accuracy and efficiency in BC diagnosis, largely attributed to utilization of convolution neural network(CNNs), and some of them have already achieved radiologist-like level. On the other hand, radiologists' performance on BC screening has shown to be enhanced, by leveraging AI-CAD system as decision support tool. As increasing implementation of commercial AI-CAD system, robust evaluation of its usefulness and cost-effectiveness in clinical circumstances should be undertaken in scenarios mimicking real life before broad adoption, like other emerging and promising technologies. This requires to validate AI-CAD systems in BC screening on multiple, diverse and representative datasets and also to estimate the interface between reader and system. This proposed study seeks to investigate the breast cancer diagnostic performance of AI-CAD system used for reading mammograms. In this work, we will employ a commercially available AI-CAD tool based on deep-learning algorithms (IBM Watson Imaging AI Solution) to identify and characterize the suspicious breast lesions on mammograms. The potential cancer lesions can be labeled and their mammographic features and malignancy probability will be automatically reported. After AI post-processing, we shall further carry out statistical analysis to determine the accuracy of AI-CAD system for BC risk prediction.

Treatments tested

  • mammography

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Breast Cancer Screening With Mammography: Diagnostic Assessment of an Artificial
Record updated
7 February 2024